GRAIL (NASDAQ:GRAL) Announces Quarterly Earnings Results

GRAIL (NASDAQ:GRAL) released its quarterly earnings results on Wednesday. The company reported ($2.21) EPS for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.24, FiscalAI reports. The business had revenue of $37.53 million during the quarter, compared to analysts’ expectations of $44.21 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%.

Here are the key takeaways from GRAIL’s conference call:

• Galleri received a favorable FDA advisory committee vote, with GRAIL expecting an FDA decision by early Q1 2027. The company said discussions with the FDA are active, including label negotiations, but no decision date has been provided.
• GRAIL highlighted clinical results showing Galleri detected 4–6.5 times more cancers when added to standard screening, with nearly half of detected cancers at stages 1 or 2; it also reported a 20% reduction in stage 4 diagnoses for a prespecified group of 12 cancers. However, the NHS-Galleri trial did not show a reduction in the combined incidence of stage 3 and 4 cancers.
• Test volume rose 24% year over year in Q3 and 36% in the first nine months, with the company citing provider activation and reactivation. GRAIL is expanding sales, health-system integrations and marketing, while using promotional pricing to encourage demand ahead of a potential FDA decision.
• Q3 revenue increased just 4% to $37.5 million despite 24% volume growth, as lower average selling prices weighed on results. Adjusted gross margin fell to 42% from 55%, adjusted EBITDA loss widened 29%, and GRAIL lowered full-year Galleri sales revenue growth guidance to 17%–21%; the Illumina royalty is also expected to resume in late December.
• GRAIL ended the quarter with $788.7 million in cash and said its cash position provides runway into 2029; its 2026 cash-burn guidance of no more than $300 million was unchanged.

GRAIL Price Performance

GRAL stock traded down $24.01 during trading on Thursday, hitting $119.65. 1,272,812 shares of the stock traded hands, compared to its average volume of 975,139. The stock has a market cap of $5.34 billion, a price-to-earnings ratio of -12.21 and a beta of 2.86. GRAIL has a 1 year low of $41.50 and a 1 year high of $166.48. The firm’s 50 day moving average is $115.58 and its two-hundred day moving average is $79.12.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Royal Bank Of Canada initiated coverage on GRAIL in a research note on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 target price on the stock. UBS Group upped their price target on GRAIL from $105.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Guggenheim lifted their price objective on GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Mizuho boosted their target price on GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a research note on Friday, September 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $119.80.

Insider Activity

In related news, CFO Aaron Freidin sold 23,619 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $3,457,585.41. Following the sale, the chief financial officer owned 225,364 shares in the company, valued at approximately $32,991,035.96. This trade represents a 9.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Joshua Ofman sold 61,452 shares of GRAIL stock in a transaction on Monday, September 21st. The stock was sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the transaction, the chief executive officer owned 362,271 shares in the company, valued at $35,408,367.54. This represents a 14.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 129,944 shares of company stock valued at $14,832,805 over the last ninety days. 1.83% of the stock is currently owned by corporate insiders.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: The FDA advisory committee voted in favor of approval of GRAIL’s Galleri multi-cancer early-detection test. The FDA decision is still pending, with an expected decision in early 2027. GRAIL Q3 results
• Positive Sentiment: Galleri test volume increased about 24% year over year to more than 56,000 in Q3, while revenue grew 14% to $37.3 million. GRAIL Q3 results
• Positive Sentiment: GRAIL’s quarterly loss of $2.21 per share was narrower than analysts’ expected loss of $2.45. GRAIL earnings results
• Negative Sentiment: Revenue of about $37.5 million fell short of the roughly $44.2 million analyst consensus. The miss raises concerns about the pace of commercial adoption, even as test volumes grow. GRAIL misses sales expectations
• Negative Sentiment: GRAIL is reducing Galleri prices to encourage adoption ahead of the FDA decision. The lower pricing may support test demand, but could weigh on revenue growth and margins. GRAIL earnings call pricing outlook

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.